Compare MUC & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUC | AMPH |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.9M | 1.0B |
| IPO Year | 1997 | 2005 |
| Metric | MUC | AMPH |
|---|---|---|
| Price | $9.80 | $25.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 639.5K | 418.3K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $3.87 |
| Revenue Next Year | N/A | $4.90 |
| P/E Ratio | ★ N/A | $33.02 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.56 | $16.65 |
| 52 Week High | $11.16 | $29.52 |
| Indicator | MUC | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 26.89 | 61.99 |
| Support Level | N/A | $18.51 |
| Resistance Level | $10.89 | $29.40 |
| Average True Range (ATR) | 0.12 | 1.00 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 27.27 | 51.04 |
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes. The fund mainly invests in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and California personal income taxes. Under normal market conditions, it invests a majority of its managed assets in investment-grade municipal obligations with remaining maturities of one year or more at the time of investment. It can also invest in below investment-grade securities, or directly in such securities or synthetically through the use of derivatives.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.